Therapeutic approaches to inflammation in neurodegenerative disease.
about
Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studiesNon-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studiesSystemic administration of an antagonist of the ATP-sensitive receptor P2X7 improves recovery after spinal cord injuryPotential therapeutic interest of adenosine A2A receptors in psychiatric disorders.Relevance of chronic stress and the two faces of microglia in Parkinson's diseaseAlzheimer's therapeutics: translation of preclinical science to clinical drug developmentThe role of free radicals in the aging brain and Parkinson's Disease: convergence and parallelismA new look at auranofin, dextromethorphan and rosiglitazone for reduction of glia-mediated inflammation in neurodegenerative diseasesSex differences in Parkinson's diseaseThe newly synthesized pool of dopamine determines the severity of methamphetamine-induced neurotoxicityNeuroimmune crosstalk in the central nervous system and its significance for neurological diseasesMining relational paths in integrated biomedical dataGastrodin inhibits expression of inducible NO synthase, cyclooxygenase-2 and proinflammatory cytokines in cultured LPS-stimulated microglia via MAPK pathwaysSpecific changes of serum proteins in Parkinson's disease patientsAcacetin inhibits glutamate release and prevents kainic acid-induced neurotoxicity in ratsMitochondrial therapy for Parkinson's disease: neuroprotective pharmaconutrition may be disease-modifyingNitrated alpha-synuclein and microglial neuroregulatory activities.Association of fibrinogen with Parkinson disease in elderly Japanese-American men: a prospective studyMicroglia in the aging brain: relevance to neurodegenerationRelationship between tau pathology and neuroinflammation in Alzheimer's disease.Resveratrol inhibits inflammatory responses via the mammalian target of rapamycin signaling pathway in cultured LPS-stimulated microglial cells.Bioactive compounds from macroalgae in the new millennium: implications for neurodegenerative diseases.Prostaglandin J2: a potential target for halting inflammation-induced neurodegeneration.P2Y receptors in Alzheimer's disease.Neuroinflammation and J2 prostaglandins: linking impairment of the ubiquitin-proteasome pathway and mitochondria to neurodegeneration.Adult human glia, pericytes and meningeal fibroblasts respond similarly to IFNy but not to TGFβ1 or M-CSF.The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease.Inflammatory Animal Model for Parkinson's Disease: The Intranigral Injection of LPS Induced the Inflammatory Process along with the Selective Degeneration of Nigrostriatal Dopaminergic Neurons.Peripheral vs. Central Sex Steroid Hormones in Experimental Parkinson's Disease.Histone deacetylase inhibitor SAHA attenuates post-seizure hippocampal microglia TLR4/MYD88 signaling and inhibits TLR4 gene expression via histone acetylationEffects of neuroinflammation on the regenerative capacity of brain stem cellsModulation of Lipopolysaccharide Stimulated Nuclear Factor kappa B Mediated iNOS/NO Production by Bromelain in Rat Primary Microglial Cells.Carriers of the fragile X mental retardation 1 (FMR1) premutation allele present with increased levels of cytokine IL-10.Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression.Anti-inflammatory effects of dimemorfan on inflammatory cells and LPS-induced endotoxin shock in mice.Celecoxib reduces brain dopaminergic neuronaldysfunction, and improves sensorimotor behavioral performance in neonatal rats exposed to systemic lipopolysaccharide.Dopamine disposition in the presynaptic process regulates the severity of methamphetamine-induced neurotoxicity.alpha-Synuclein: a therapeutic target for Parkinson's disease?Methamphetamine-induced neurotoxicity and microglial activation are not mediated by fractalkine receptor signalingImmunological features of alpha-synuclein in Parkinson's disease.
P2860
Q24235107-99D153E3-E67E-43E2-A306-825B3CEF412AQ24236199-1BF79D05-7EB5-491F-B153-6D1E07A85A0DQ24642504-5E15B0B7-3610-438C-9278-74C3F6EAF8C9Q24657796-C2EFAC33-BB7C-48AB-B6AD-4EF43A04A494Q26796241-641C8D3B-CAC7-4379-974D-F3A71DBC8E6FQ26829267-901BED6F-65C4-4A83-8FB7-571952603792Q26852148-8536D073-D4CB-4F34-8DF3-8F9E310110F0Q27005806-841E674D-71CC-42B4-93CB-3CF0BA0C823BQ27025107-B1E523A1-FF60-4124-A49A-E40A01175F41Q28261448-06B76DBB-05F4-438C-B9F3-AAC8FC35F066Q28269903-01096984-BB8E-4F55-83EC-AF427B55FC61Q28478280-FBC3A78F-8697-48D0-A661-9ABCD92CBC27Q28478996-88FAED0F-9806-40C0-8A49-569A9AC0192CQ28538260-73657974-E383-4354-994E-8C72BBDCEA04Q28539687-E4D8D2CD-EA8B-4F47-95A3-6202AF36FE67Q28732683-E3396FBE-0124-4831-AB1F-EFAF9815DE7FQ33315262-F1222723-2B31-4F98-BF16-0B6D803DD9DFQ33637422-FEC5FECB-A6A6-4DDB-A7C5-8B1A0A1A9DA5Q33780335-E1229B4F-7C6C-47D1-9C99-2B78849F1214Q33995490-E394C970-E12D-4F7E-86B6-D577B28507CDQ34171717-7B3AF367-1E02-4C79-A8FE-7803EEC07239Q34260323-EC6DD60A-246A-4C8E-BEC9-797D6424C3DAQ34508284-11117E8E-E4ED-4A8C-A55D-B853A4375538Q34860664-2489342B-FA59-446B-B9F5-C0D9A0D08275Q34933261-342A75FE-C858-463C-A7BC-F43F0E968725Q35067317-96A71E95-2661-4B59-917B-DDC9B0752388Q35628604-CD18A991-2F8F-4A22-A8A6-8E13B185A681Q35687315-A5CA580B-8499-4D2D-9B95-72990B2220A4Q35971342-9F9DD682-EC64-44CE-8DF6-8FA2E4B31C2AQ36021545-28D7CF54-5AB2-4ABA-9DF2-0749D8282BCFQ36055590-33652725-EDE7-4546-9622-A304DA857F09Q36399086-79C881C5-BAD3-4944-B0DB-5BC238F84694Q36483349-8DD50163-BDA2-46A4-B6B7-362FA4ABC858Q36692860-586E7454-C2BB-45C0-8CB5-885C8252B15FQ36790190-8780B89C-550A-4419-8542-72DBC9AE5724Q36798371-8FF228E3-83F0-4396-A320-9B81E8AD8A9BQ36996142-4D005A4C-A596-4FE6-A661-C269E9E1749CQ37070916-23839027-BCBB-4405-AAEE-7756F9BEEC94Q37156342-07CA6843-1E8D-4A49-9DBD-AC1B36A35C2AQ37232067-08372968-5FDD-41F1-A65D-EAE30A99DF8B
P2860
Therapeutic approaches to inflammation in neurodegenerative disease.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Therapeutic approaches to inflammation in neurodegenerative disease.
@ast
Therapeutic approaches to inflammation in neurodegenerative disease.
@en
type
label
Therapeutic approaches to inflammation in neurodegenerative disease.
@ast
Therapeutic approaches to inflammation in neurodegenerative disease.
@en
prefLabel
Therapeutic approaches to inflammation in neurodegenerative disease.
@ast
Therapeutic approaches to inflammation in neurodegenerative disease.
@en
P2093
P1476
Therapeutic approaches to inflammation in neurodegenerative disease.
@en
P2093
Andis Klegeris
Edith G McGeer
Patrick L McGeer
P304
P356
10.1097/WCO.0B013E3280ADC943
P577
2007-06-01T00:00:00Z